Literature DB >> 24458879

Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.

Massimo Breccia1, Maria Teresa Voso, Luca Maurillo, Pasquale Niscola, Luana Fianchi, Maria Antonietta Aloe Spiriti, Francesco Buccisano, Roberto Latagliata, Sabrina Pelliccia, Susanna Fenu, Andrea Tendas, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24458879     DOI： 10.1002/ajh.23677

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.

Authors:  Andrea Tendas; Maria Felicita Lissia; Daniela Piccioni; Liliana Tirimbelli; Laura Scaramucci; Marco Giovannini; Teresa Dentamaro; Alessio Perrotti; Paolo de Fabritiis; Pasquale Niscola
Journal:  Support Care Cancer       Date:  2014-11-05       Impact factor: 3.603

2.  Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.

Authors:  Pasquale Niscola; Andrea Tendas; Roberta Merola; Giulia Orlandi; Laura Scaramucci; Paolo de Fabritiis
Journal:  Blood Res       Date:  2015-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.